Related Experiment Video
Updated: May 13, 2025
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
Acute myocardial infarction after batroxobin treatment of sudden sensorineural hearing loss: Case report
Yinping Lu1, Yingxin Liu1, Weiliang Tang2
1Department of Otorhinolaryngology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Rationale:
The drug batroxobin is utilized to enhance microcirculation by reducing fibrinogen levels, making it a treatment option for the acute stage of severe sudden sensorineural hearing loss (SSNHL). However, the efficacy of batroxobin defibrination remains controversial. It is crucial to also consider the potential thrombotic effects of batroxobin. This is the first report of acute myocardial infarction (AMI) in patients after treatment for SSNHL with batroxobin, aiming to enhance its clinical safety profile.
Patient Concerns:
A 61-year-old male patient presented with severe SSNHL in the left ear. During hospitalization, the plasma fibrinogen level remained consistently low following batroxobin treatment and subsequently led to AMI.
Diagnoses:
SSNHL, AMI.
Interventions:
Percutaneous coronary intervention surgery confirmed thrombus blockage in the middle segment of the right coronary artery, and the symptoms were relieved after thrombus removal.
Outcomes:
The patient was discharged from the hospital on the 5th day after surgery without any recurrence of AMI up to now.
Lessons:
The pharmacology and toxicity of batroxobin are intricate, necessitating careful consideration of potential secondary thrombosis during treatment, particularly regarding fibrinogen levels.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:31Hearing
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...